Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Abiad Visits the Karantina Warehouse and Public Hospital with a Delegation from the Republic of Korea and UNICEF

 
Following the announcement of new contribution from the Republic of Korea to ensure new-borns’ lifesaving care across selected governmental hospitals and the availability of essential paediatric acute medications in primary healthcare centres, the minister of public health held a joint field visit to the Karantina warehouse and hospital with Korean Ambassador to Lebanon and UNICEF Representative. 

The new funding will ensure the access of vulnerable populations to essential medications at primary healthcare centres and intensive lifesaving care services in public hospitals to avoid any supply rupture and allow timely access to acute treatments for children and mothers.  

The Minister of Public Health, Dr. Firass Abiad, indicated that "this donation will contribute to supporting the most vulnerable". He pointed out that "this is not the first time that the Republic of Korea  and UNICEF have stood by Lebanon.  through cooperation with partners, the Ministry of Public Health, in light of the difficult economic and political circumstances in Lebanon and the fact that Lebanon is hosting large numbers of displaced people, is trying to fulfill its duties towards everyone by providing health services and medicine in Primary health care centers".

Ambassador of the Republic of Korea in Lebanon, Mr.  Il Park said: “Korea recognizes the importance of providing essential healthcare services to the most vulnerable members of society, particularly children and newborns. We firmly believe that every child deserves the right to receive proper medical attention and care, regardless of their circumstances.”

The procured acute medications includes antibiotics, and anti-inflammatories allow to fill the gap in the acute medication supply induced by high demand for care from the most vulnerable children in Lebanon. Supporting vulnerable families to cover the out of pocket payment for their infants and children intensive care services helps eliminate the financial barrier to accessing lifesaving care. 

Edouard Beigbeder, UNICEF Representative in Lebanon, emphasized the organization's dedication to bridging vital healthcare access disparities and maintaining life-saving assistance for mothers and children in Lebanon. “Thanks to the ongoing generous support from the Republic of Korea, we can broaden our initiatives to encompass more vulnerable areas and additional hospitals, with a particular focus on enhancing support in Baalbek and Akkar."
    ...
    128
    ...
ATC Name B/G Ingredients Dosage Form Price
L01EB02 APO-ERLOTINIB G Erlotinib (HCl) - 100mg 100mg Tablet 79,672,726 L.L
L01EB02 MIRATA G Erlotinib (HCl) - 100mg 100mg Tablet, film coated 77,379,009 L.L
L01EB02 TARESSA 100 G Erlotinib (HCl) - 100mg 100mg Tablet, film coated 82,247,256 L.L
L01XX41 HALAVEN B Eribulin mesylate - 0.88mg/2ml 0.88mg/2ml Injectable solution 35,421,768 L.L
L01XX41 HALAVEN B Eribulin mesylate - 0.88mg/2ml 0.88mg/2ml Injectable solution L.L
N02CD01 AIMOVIG BioTech Erenumab - 70mg/ml 70mg/ml Injectable solution 35,423,371 L.L
B02BD08 ARYOSEVEN RT BioTech Eptacog alfa - 1mg 1mg Injectable powder for solution+diluent 16,902,713 L.L
B02BD08 ARYOSEVEN RT BioTech Eptacog alfa - 1mg 1mg Injectable powder for solution+diluent L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 5mg 5mg (250KIU) Injectable powder for solution+diluent 275,482,577 L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 2mg 2mg (100KIU) Injectable powder for solution+diluent 110,192,512 L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 1mg 1mg (50KIU) Injectable powder for solution+diluent 60,204,155 L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 1mg 1mg (50KIU) Injectable powder for solution+diluent L.L
B02BD08 RECOFACT VII BioTech Eptacog alfa (activated) recombinant - 1.2mg 1.2mg Injectable powder for solution+diluent 47,533,131 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 50mg 50mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 50mg 50mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 50mg 50mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE BIOGARAN G Eplerenone - 50mg 50mg Tablet, coated 1,849,127 L.L
C03DA04 HEPERONA 50 G Eplerenone - 50mg 50mg Tablet, coated 2,150,148 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 25mg 25mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 25mg 25mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 25mg 25mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE BIOGARAN G Eplerenone - 25mg 25mg Tablet, coated 1,849,127 L.L
C03DA04 HEPERONA 25 G Eplerenone - 25mg 25mg Tablet, coated 2,116,552 L.L
L01DB03 EPIRUBICINE VIATRIS 2MG/ML G Epirubicin HCl - 50mg/25ml 50mg/25ml Injectable solution 3,914,242 L.L
L01DB03 EPIRUBICINE VIATRIS 2MG/ML G Epirubicin HCl - 10mg/5ml 10mg/5ml Injectable solution 855,212 L.L
C01CA24 ADRENALINE RENAUDIN G Epinephrine (tartrate) - 1mg/ml 1mg Injectable solution 444,812 L.L
C01CA26 EPHEDRINE AGUETTANT G Ephedrine HCl - 3mg/ml 3mg/ml Injectable solution 7,827,491 L.L
C01CA26 EPHEDRINE AGUETTANT G Ephedrine HCl - 30mg/ml 30mg/ml Injectable solution 614,136 L.L
C01CA26 EPHEDRINE RENAUDIN G Ephedrine HCl - 30mg/ml 3% Injectable solution 693,423 L.L
D08AX02 EOSIN ALCOHOLIC G Eosin - 2% 2% Solution 115,187 L.L
    ...
    128
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025